We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for ... Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. Show more
WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (โMustangโ or the โCompanyโ) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating todayโs...
MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial Preclinical data support a novel combination of MB-108 (HSV-1...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0204 | -10.2 | 0.2 | 0.2044 | 0.1539 | 827397 | 0.17561327 | CS |
4 | -0.0234 | -11.5270935961 | 0.203 | 0.2167 | 0.1539 | 640146 | 0.18817153 | CS |
12 | -0.0699 | -28.0160320641 | 0.2495 | 0.3701 | 0.1539 | 1909457 | 0.27344508 | CS |
26 | -0.3904 | -68.4912280702 | 0.57 | 0.8588 | 0.1539 | 3077389 | 0.41715506 | CS |
52 | -1.1904 | -86.8905109489 | 1.37 | 1.53 | 0.1281 | 8012398 | 0.65037867 | CS |
156 | -27.1204 | -99.3421245421 | 27.3 | 29.55 | 0.1281 | 2984394 | 1.82459664 | CS |
260 | -49.7704 | -99.6404404404 | 49.95 | 78.3 | 0.1281 | 2379566 | 14.08025168 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions